Antigen presentation: Lysoyme, autoimmune diabetes, and listeria - What do they have in common?

Immunologic Research

Volumn 32, Issue 1-3, 2005, Pages 267-292

  Unanue, Emil ^a   Byersdorfer, Craig ^a   Carrero, Javier ^a   Levisetti, Matteo ^a   Lovitch, Scott ^a   Pu, Zheng ^a   Suri, Anish ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presentation; Antigen processing; Diabetes mellitus; Histocompatibility molecules; Listeria monocytogenes; Lymphocyte apoptosis; Nonobese diabetic mouse

Indexed keywords

ANTIBODY; ASPARTYLTYROSYLGLYCYLISOLEUCYLLEUCYLGLUTAMINYLISOLEUCYLASPARAGINYLSERINE; AUTOANTIBODY; EGG WHITE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12 RECEPTOR; LISTERIOLYSIN; LISTERIOLYSIN O; LISTERIOLYSIN O ANTIBODY; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 MOLECULE I A G7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 MOLECULE I AK; MONOCLONAL ANTIBODY; PEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ACIDITY; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHANNEL GATING; DIABETES MELLITUS; DISEASE PREDISPOSITION; EPITOPE MAPPING; GENE DELETION; HAPLOTYPE; HEN; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; ISOMER; LISTERIA; LISTERIOSIS; LYMPH NODE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; APOPTOSIS; AUTOANTIBODIES; CHICKENS; DIABETES MELLITUS, TYPE 1; EPITOPES; LISTERIA INFECTIONS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; MURAMIDASE; PROTEIN CONFORMATION; T-LYMPHOCYTE SUBSETS;

EID: 23844431564     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:32:1-3:267     Document Type: Review

References (131)

1. Allen PM, Unanue ER: Antigen processing and presentation by macrophages. Am J Anat 1984;170:483-490.
2. Gammon G, Shastri N, Cogswell J, et al: The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev 1987;98:53-73.
3. Moudgil KD, Sekiguchi D, Kim SY, Sercarz EE: Immunodominance is independent of structural constraints: each region within hen eggwhite lysozyme is potentially available upon processing of native antigen. J Immunol 1997;159:2574-2579.
4. Allen PM, Strydom DJ, Unanue ER: Processing of lysozyme by macrophages: identification of the determinant recognized by two T cell hybridomas. Proc Natl Acad Sci USA 1984;81:2489-2495.
5. Shimonkevitz R, Kappler J, Marrack P, Grey H: Antigen recognition by H-2 restricted T cells: cell-free antigen processing. J Exp Med 1983;158:303-316.
6. Ziegler K, Unanue ER: Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to lymphocytes. J Immunol 1981;127:1869-1877.
7. Ziegler K, Unanue ER: Decrease in macrophage antigen catabolism by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982;78:175-180.
8. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER: Binding of immunogenic peptides to 1a histocompatibility molecules. Nature 1985;317:359-362.
9. Babbitt BP, Matsueda G, Haber E, Unanue ER, Allen PM: Antigenic competition at the level of peptide-1a binding. Proc Natl Acad Sci USA 1986;83:4509-4513.
10. Lindner R, Unanue ER: Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J 1996;15:6910-6920.
11. k. Proc Natl Acad Sci USA 1992;89:7380-7383.
12. k. J Immunol 1996;157:755-762.
13. k by using peptide-specific immunoaffinity. J Immunol 1998;161:6074-6083.
14. k molecules of two epitopes found in tandem in an extended polypeptide. J Immunol 2000;165:3206-3213.
15. k histocompatibility molecules. J Biol Chem 2002;277:42,514-42,522.
16. d. Science 1992;256:1817-1820.
17. Chicz RM, Urban RG, Lane WS, et al: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992;358:764-768.
18. Rudensky AY, Preston-Hurlburt P, Al-Ramadi BK, Rothbard J, Janeway CA Jr: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992;359:429-431.
19. Velazquez C, DiPaolo R, Unanue ER: Quantitation of lysozyme peptides bound to class II MHC molecules indicates very large differences in levels of presentation. J Immunol 2001;166:5488-5494.
20. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER: Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 1997;6:727-738.
21. Zhong G, Romagnoli P, Germain RN: Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class II molecules control endocytic presentation of distinct determinants in a single protein. J Exp Med 1997;185:429-438.
22. Baldwin KK, Reay PA, Wu L, Farr A, Davis MM: A T cell receptor-specific blockade of positive selection. J Exp Med 1999;189:13-24.
23. Dongre AR, Kovats S, deRoos P, et al: In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol 2001;31:1485-1494.
24. Vignali DA, Urban RG, Chicz RM, Strominger JL: Minute quantities of a single dominant foreign epitope are presented as large nested sets by major histocompatibility complex class II molecules. Eur J Immunol 1993;23:1602-1613.
25. Vignali DA, Strominger JL: Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J Exp Med 1994;179: 1945-1956.
26. Nelson CA, Fremont DH: Structural principles of MHC class II antigen presentation. Rev Immunogenet 1999;1:47-59.
27. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J: Crystal structure of mouse H2-M. Immunity 1998;9:385-393.
28. Fremont DH, Hendrickson WA, Marrack P, Kappler J: Structures of an MHC class II molecule with covalently bound single peptides. Science 1996;272:1001-1004.
29. g7 and autoimmune diabetes. Science 2000;288:505-511.
30. Scott CA, Peterson PA, Teyton L, Wilson IA: Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 1998;8:319-329.
31. Brown JH, Jardetzky TS, Gorga JC, et al: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
32. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC: X-ray crystal structure of HLA-DR4 (DRA*0101, DRB 1*0401) complexed with a peptide from human collagen II. Immunity 1997;7:473-481.
33. Jardetzky TS, Brown JH, Gorga JC, et al: Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994;368:711-718.
34. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER, Fremont DH: Structural basis of peptide binding and presentation by the type 1 diabetes-associated MHC class II molecule of NOD mice. Immunity 2000;12:699-710.
35. Jardetzky TS, Gorga JC, Busch R, Rothbard J, Strominger JL, Wiley DC: Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J 1990;9:1797-1803.
36. k class II molecules. Proc Natl Acad Sci USA 2000;97:11,460-11,465.
37. Pu Z, Carrero JA, Unanue ER: Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. Proc Natl Acad Sci USA 2002;99:8844-8849.
38. Allen PM, Matsueda GR, Evans RJ, Dunbar JB Jr, Marshall G, Unanue ER: Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature 1987;327:713-715.
39. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER: Liposome-capsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell 1991;64:393-401.
40. Collins DS, Unanue ER, Harding CV: Reduction of disulphide bonds within lysosomes is a key step in antigen processing. J Immunol 1991;147:4054-4059.
41. Pu Z, Lovitch SB, Bikoff EK, Unanue ER: T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 2004;20: 467-476.
42. Jensen PE: Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant. J Exp Med 1991;174:1121-1130.
43. Arunachalam B, Phan UT, Dong C, et al: Defective antigen processing in GILT-free mice. Science 2001;294:1361-1365.
44. Donermeyer DL, Allen PM: Binding to Ia protects an immunogenic peptide from proteolytic degradation. J Immunol 1989;142:1063-1068.
45. Werdelin O, Mouritsen S, Peterson BL, Sette A, Buus S: Facts on the fragmentation of antigens in presenting cells, on the association of antigen fragments with MHC molecules in cell-free systems, and speculation on the cell biology of antigen processing. Immunol Rev 1988;106:181-193.
46. Carrasco-Marin E, Petzold S, Unanue ER: Two structural states of peptide-class II MHC complexes revealed by photoaffinity labeled peptides. J Biol Chem 1999;274:31,333-31,340.
47. Nelson CA, Vidavsky I, Viner NJ, Gross ML, Unanue ER: Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1997;94: 628-633.
48. Rammensee HG, Friede T, Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
49. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Mougdil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-766.
50. k-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity. Proc Natl Acad Sci USA 1995;92:2214-2218.
51. Viner NJ, Nelson CA, Deck B, Unanue ER: Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 1996;156:2365-2368.
52. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER: Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 1999;11:453-462.
53. Cirrito TP, Pu Z, Deck MB, Unanue ER: Deamidation of asparagine in a major histocompatibility complex-bound peptide affects T cell recognition but does not explain type B reactivity. J Exp Med 2001;194:1165-1170.
54. Sloan VS, Cameron P, Porter G, et al: Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
55. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ: Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15: 6144-6154.
56. van Ham SM, Gruneberg U, Malcherek G, Broker I, Melms A, Trowsdale J: Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996;184:2019-2024.
57. k during antigen processing. J Immunol 2003;171:2183-2186.
58. Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED: Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 2000;13:517-527.
59. Marrack P, Ignatowicz L, Kappler JW, Boymel J, Freed JH: Comparison of peptides bound to spleen and thymus class II. J Exp Med 1993;178:2173-2183.
60. k-derived peptides that are autoantigenic to type B T cells. J Immunol 2003;170:4155-4160.
61. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, Stern LJ: Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci USA 1999;96:15,056-15,061.
62. Barlow AK, He X, Janeway CA Jr: Exogenously provided peptides of a self-antigen can be processed into forms that are recognized by self-T cells. J Exp Med 1998;187:1403-1415.
63. Viret C, He X, Janeway CA Jr: Paradoxical intrathymic positive selection in mice with only a covalently presented agonist peptide. Proc Natl Acad Sci USA 2001;98:9243-9248.
64. Viret C, He X, Janeway CA Jr: Altered positive selection due to corecognition of floppy peptide/MHC II conformers supports an integrative model of thymic selection. Proc Natl Acad Sci USA 2003;100: 5354-5359.
65. u conformers in murine experimental autoimmune encephalomyelitis. J Immunol 2003;171:2467-2477.
66. Hulsmeyer M, Fiorillo M, Fiorillo, MT, et al: Dual, HLA-B27 subtype-dependent conformation of a self-peptide. J Exp Med 2004;199:271-281.
67. Beeson C, Anderson TG, Lee C, McConnell HM: Isomeric complexes of peptides with class II proteins of the major histocompatibility complex. J Am Chem Soc 1995;117:10,429-10,433.
68. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER: Cutting edge: negative selection of immature thymocytes by a few peptide-MHC complexes: differential sensitivity of immature and mature T cells. J Immunol 1999;162:3117-3120.
69. Reay PA, Matsui K, Haase K, Wulfing C, Chien YH, Davis MM: Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies. J Immunol 2000;164:5626-5634.
70. Pape KA, Khoruts A, Mondino A, Jenkins MK: Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997;159:591-598.
71. Ho WY, Cooke MP, Goodnow CC, Davis MM: Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med 1994;179:1539-1549.
72. Akkaraju S, Ho WY, Leong D, Canaan K, Davis MM, Goodnow CC: A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity 1997; 7:255-271.
73. DiPaolo RJ, Unanue ER: The level of peptide-MHC complex determines the susceptibility to autoimmune diabetes: studies in HEL transgenic mice. Eur J Immunol 2001;31:3453-3459.
74. Anderson MS, Venanzi ES, Lein L, et al: Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-1400.
75. Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC: Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003;4:350-354.
76. Venanzi ES, Benoist C, Mathis M: Good riddance: thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 2004;16:197-214.
77. Kanagawa O, Martin SM, Vaupel BA, Carrasco-Marin E, Unanue ER: Autoreactivity of T cells from nonobese diabetic mice: an I-Ag7-dependent reaction. Proc Natl Acad Sci USA 1998;95:1721-1724.
78. DiPaolo RJ, Unanue ER: Cutting edge: chemical dominance does not relate to immunodominance: studies of the CD4+ T cell response to a model antigen. J Immunol 2002;169:1-4.
79. Castigli E, Alt FW, Davidson L, et al: CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 1994;91:12,135-12,141.
80. Borriello F, Sethna MP, Boyd SD, et al: B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 1997;6:303-311.
81. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998;187:427-432.
82. DiPaolo RJ, Unanue ER: Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways. J Immunol 2002;169:2832-2836.
83. Byersdorfer C, DiPaolo R, Petzold S, Unanue E: Following immunization antigen becomes concentrated in a limited number of antigen presenting cells including B cells. J Immunol 2004, 173:6627-6634.
84. Creusot RJ, Thomsen LL, Tite JP, Chain BM: Local cooperation dominates over competition between CD4+ T cells of different antigen/MHC specificity. J Immunol 2003;171:240-246.
85. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, Marrack P: T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000;192:1105-1113.
86. Todd JA, Bell JI, McDevitt HO: HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599-604.
87. Lee KH, Wucherpfennig KW, Wiley DC: Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001;2: 501-507.
88. Gregori S, Bono E, Gallazzi F, Hammer J, Harrison LC, Adorini L: The motif for peptide binding to the insulin-dependent diabetes mellitus-associated class II MHC molecule I-A(g7) validated by phage display library [in process citation]. Int Immunol 2000;12:493-503.
89. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER: The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 1996;156:450-458.
90. Carrasco-Marin E, Kanagawa O, Unanue ER: The lack of consensus for I-A(g7)-peptide binding motifs: is there a requirement for anchor amino acid side chains? Proc Natl Acad Sci USA 1999;96:8621-8626.
91. Bhatnagar A, Milburn PJ, Lobigs M, Blanden RV, Gautam AM: Nonobese diabetic mice display elevated levels of class II-associated invariant chain peptide associated with I-Ag7 on the cell surface. J Immunol 2001;166:4490-4497.
92. Suri A, Vidavsky I, van der Drift K, Kanagawa O, Gross ML, Unanue ER: In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket. J Immunol 2002;168:1235-1243.
93. Suri A, Walters JJ, Kanagawa O, Gross ML, Unanue ER: Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: the lack of competition. Proc Natl Acad Sci USA 2003;100: 5330-5335.
94. Quartey-Papafio R, Lund T, Chandler P, et al: Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J Immunol 1995;154:5567-5575.
95. Singer SM, Tisch R, Yang XD, McDevitt HO: An Abd transgene prevents diabetes in nonobese diabetic mice by inducing regulatory T cells. Proc Natl Acad Sci USA 1993;90:9566-9570.
96. Deng H, Apple R, Clare-Salzler M, et al: Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med 1993;178: 1675-1680.
97. McDevitt HO: The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opin Immunol 1998;10:677-681.
98. Chao CC, McDevitt HO: Identification of immunogenic epitopes of GAD 65 presented by Ag7 in non-obese diabetic mice. Immunogenetics 1997;46:29-34.
99. Bockova J, Elias D, Cohen IR: Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J Autoimmun 1997;10:323-329.
100. Reizis B, Eisenstein M, Bockova J, et al: Molecular characterization of the diabetes-associated mouse MHC class II protein, I-Ag7. Int Immunol 1997;9:43-51.
101. Bottazzo GF, Florin-Christensen A, Doniach D: Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-1283.
102. Baekkeskov S, Aanstoot HJ, Christgau S, et al: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-156.
103. Rabin DU, Pleasic SM, Shapiro JA, et al: Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 1994; 152:3183-3188.
104. Castano L, Eisenbarth GS: Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-679.
105. Levisetti MG, Suri S, Vidavsky I, Gross ML, Kanagawa O, Unanue ER: Autoantibodies and CD4 T cells target a beta cell retroviral envelope protein in non-obese diabetic mice. Int Immunol 2003;15:1473-1483.
106. Lane FC, Unanue ER: Requirement of T (thymus) lymphocytes for resistance to listeriosis. J Exp Med 1972;135:1104-1112.
107. Beller DI, Kiely J-M, Unanue ER: Regulation of macrophage populations. I. Preferential induction of Ia-rich peritoneal exudates by immunological stimuli. J Immunol 1980;124:1426-1432.
108. Farr AG, Dorf ME, Unanue ER: Secretion of mediators following T lymphocyte-macrophage interaction is regulated by the major histocompatibility complex. Proc Natl Acad Sci USA 1977;74:3542-3546.
109. Bancroft GJ, Bosma MJ, Bosma GC, Unanue ER: Regulation of macrophage Ia expression in mice with severe combined immunodeficiency: induction of Ia expression by a T cell independent mechanism. J Immunol 1986;137:4-9.
110. Unanue ER: Studies in Listeriosis show the strong symbiosis between the innate cellular system and the T cell response. Immunol Rev 1997;158:11-25.
111. Edelson BT, Unanue ER: Immunity to Listeria infection. Curr Opin Immunol 2000;12:425-431.
112. Portnoy DA, Tweten RK, Kehoe M, Bielecki J: Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect Immun 1992;60:2710-2717.
113. Bielecki J, Youngman P, Connelly P, Portnoy DA: Bacillus subtilis expressing a haemolysin gene from Listeria monocytogenes can grow in mammalian cells. Nature 1990:345:175, 176.
114. Busch DH, Pilip IM, Vijh S, Pamer EG: Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 1998;8:353-362.
115. Harty JT, Len LL, Bevan MJ: Primary and secondary immune responses to Listeria monocytogenes. Curr Opin Immunol 1996;8:526-530.
116. Bouwer HG, Gibbins BL, Jones S, Hinrichs DJ: Antilisterial immunity includes specificity to listeriolysin O (LLO) and non-LLO-derived determinants. Infect Immun 1994;62:1039-1045.
117. Bhardwaj V, Kanagawa O, Swanson PE, Unanue ER: Chronic Listeria infection in SCID mice: requirements for the carrier state and the dual role of T cells in transferring protection or suppression. J Immunol 1998;160:376-384.
118. Merrick JC, Edelson BT, Bhardwaj V, Swanson PE, Unanue ER: Lymphocyte apoptosis during early phase of Listeria infection in mice. Am J Pathol 1997; 151:785-792.
119. Rogers HW, Callery MP, Deck B, Unanue ER: Listeria monocytogenes induces apoptosis of infected hepatocytes. J Immunol 1996;156:679-684.
120. Edelson BT, Cossart P, Unanue ER: Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection. J Immunol 1999;163:4087-4090.
121. Edelson BT, Unanue ER: Intracellular antibody neutralizes Listeria growth. Immunity 2001;14:503-512.
122. Edelson BT, Unanue ER: MyD88-dependent but TLR 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J Immunol 2002;169:3869-3875.
123. Mackaness GB: Cellular resistance to infection. J Exp Med 1962;116:381-406.
124. Carrero JA, Calderon B, Unanue ER: Listeriolysin O from Listeria monocytogenes is a lymphocyte apoptogenic molecule. J Immunol 2004;172:4866-4874.
125. Carrero JA, Calderon B, Unanue ER: Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection and apoptosis. J Exp Med 2004;200:535-540.
126. Jiang J, Lau LL, Shen H: Selective depletion of nonspecific T cells during the early stage of immune responses to infection. J Immunol 2003;171:4352-4358.
127. O'Connell RM, Saha SK, Vaidya SA, et al: Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004;200:437-445.
128. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA: Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004;200:527-533.
129. Ochsenbein AF, Fehr T, Lutz C, et al: Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999;286:2156-2159.
130. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-898.
131. Valerie A, Fadok DL, Bratton DM, et al: A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.